We are excited to invite you to the 22nd Annual International Conference of the Metabolomics Society which will take place from June 21 - 24, 2026 in Buenos Aires, Argentina.
Come visit us at booth P2 to connect with our team and learn how Bruker’s metabolomics portfolio combines TIMS-enabled mass spectrometry, biocrates standardized kits, and automated NMR solutions to accelerate comprehensive, high confidence metabolomics, lipidomics, and exposomics research, from deep coverage of complex biological matrices to the creation of robust reference data that support harmonized workflows.
We also welcome you to attend the Bruker Lunch Seminar on June 23, 2026, at 12:20 pm (ART, UTC‑3) in Salon C1, featuring expert talks on phenomic medicine and timsMetabo™‑based metabolomics and lipidomics.
We look forward to meeting you at Metabolomics 2026!
Join us and our esteemed speakers Dr. Michael Witting and Professor Julien Wist on Tuesday, June 23rd for an engaging lunch seminar highlighting how TIMS MS and NMR technologies are helping leading researchers tackle challenges in metabolomics research.
PD Dr. Michael Witting, Deputy Head Metabolomics and Proteomics, Core & Executive Manager Metabolomics, Helmholtz Munich, Munich, Germany
NIST RM 8048 is a newly released human fecal reference material designed to accelerate reproducible metabolomics and lipidomics. Built from pooled samples of vegetarian and omnivorous donors, it offers a biologically relevant, highly complex matrix for stress-testing real-world workflows. In this lunch seminar, we showcase how complementary reversed-phase and HILIC separations, combined with the power of timsMetabo, unlock deep, comprehensive coverage across polar, semi-polar, and lipid species. The result is a foundational, high-quality benchmark for this landmark reference material, including curated reference spectra and CCS values generated on timsMetabo™, providing the community with a robust starting point for harmonized, high-confidence metabolic profiling.
Julien Wist, Professor of Computational Spectroscopy, Universidad del Valle, Valle del Cauca, Colombia
Phenomic medicine requires accurate maps to estimate an individual’s disease risk. Constructing such phenotypic risk maps necessitates the vertical integration of tens of thousands of molecular phenomes to capture a broad spectrum of medical conditions; this can be achieved by integrating multiple cross-sectional disease cohorts. The inherent robustness of NMR-based phenotypes enables the harmonization of data from diverse biobanks and epidemiological cohorts, even when measured at different facilities, into a single unified dataset. This scalability is evidenced by various contributions from the International Phenome Centre Network (IPCN). Furthermore, recent technological breakthroughs, including simplified sample collection, the transition to cost-effective platforms, and AI-enhanced data analytics, have made the clinical deployment of NMR-based phenotyping a realistic prospect.
Julien Wist, Professor of Computational Spectroscopy, Universidad del Valle, Valle del Cauca, Colombia
PD Dr. Michael Witting, Deputy Head Metabolomics and Proteomics, Core & Executive Manager Metabolomics, Helmholtz Munich, Munich, Germany
Nur für die Forschung. Nicht für den Einsatz in klinischen diagnostischen Verfahren.